Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II KPd in relapsed/refractory multiple myeloma
KCT0012128Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Boryung. Primary endpoint: progression-free survival. Started Aug 2026; status: recruiting.
02
Drugs
carfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0012128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012128.